353 related articles for article (PubMed ID: 15040821)
1. Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety.
Rubin C; Recker R; Cullen D; Ryaby J; McCabe J; McLeod K
J Bone Miner Res; 2004 Mar; 19(3):343-51. PubMed ID: 15040821
[TBL] [Abstract][Full Text] [Related]
2. Low magnitude mechanical loading is osteogenic in children with disabling conditions.
Ward K; Alsop C; Caulton J; Rubin C; Adams J; Mughal Z
J Bone Miner Res; 2004 Mar; 19(3):360-9. PubMed ID: 15040823
[TBL] [Abstract][Full Text] [Related]
3. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
[TBL] [Abstract][Full Text] [Related]
4. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.
Zhang G; Qin L; Shi Y
J Bone Miner Res; 2007 Jul; 22(7):1072-9. PubMed ID: 17419678
[TBL] [Abstract][Full Text] [Related]
5. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
6. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
7. Effect of 12 months of whole-body vibration therapy on bone density and structure in postmenopausal women: a randomized trial.
Slatkovska L; Alibhai SM; Beyene J; Hu H; Demaras A; Cheung AM
Ann Intern Med; 2011 Nov; 155(10):668-79, W205. PubMed ID: 22084333
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women.
Dawson-Hughes B; Dallal GE; Krall EA; Sadowski L; Sahyoun N; Tannenbaum S
N Engl J Med; 1990 Sep; 323(13):878-83. PubMed ID: 2203964
[TBL] [Abstract][Full Text] [Related]
9. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
10. Transmissibility of 15-hertz to 35-hertz vibrations to the human hip and lumbar spine: determining the physiologic feasibility of delivering low-level anabolic mechanical stimuli to skeletal regions at greatest risk of fracture because of osteoporosis.
Rubin C; Pope M; Fritton JC; Magnusson M; Hansson T; McLeod K
Spine (Phila Pa 1976); 2003 Dec; 28(23):2621-7. PubMed ID: 14652479
[TBL] [Abstract][Full Text] [Related]
11. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
12. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
13. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
14. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
15. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
16. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
18. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
19. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
Rejnmark L; Buus NH; Vestergaard P; Heickendorff L; Andreasen F; Larsen ML; Mosekilde L
J Bone Miner Res; 2004 May; 19(5):737-44. PubMed ID: 15068496
[TBL] [Abstract][Full Text] [Related]
20. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
Greenspan SL; Beck TJ; Resnick NM; Bhattacharya R; Parker RA
J Bone Miner Res; 2005 Sep; 20(9):1525-32. PubMed ID: 16059624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
